CHIEF OPERATING OFFICER GW PHARMACEUTICALS

What prompted your decision to enter Spain?

Formally establishing our presence in Spain underscores our long-term commitment to Spanish patients and physicians and furthers GW’s mission to bring innovative cannabinoid medicines to patients with high unmet need. Spain continues to be one of Europe’s best environments for research and clinical development and is an important hub for GW Pharmaceuticals. Multiple Spanish hospitals have participated in GW clinical trials and we’re proud to currently be conducting significant levels clinical research with key health centers in Spain to investigate the potential for cannabinoid medicines in a range of rare disease areas.

How much does GW invest in R&D and scientific papers to continue learning about and promoting the benefits of cannabinoid?

Globally, GW has invested over EUR1.4 billion in research and development and the infrastructure needed to bring novel, innovative medicines to patients, and we employ over 1,000 people worldwide. Much of what is known about the medical uses of cannabis was discovered by GW. Consequently, we have initiated a robust pipeline for clinical development, pioneering significant advancements in the development of cannabis-based medicines. Through collaboration with world-leading specialists, institutions, and research organizations, we will continue to invest heavily in the research needed to accelerate the development of medicines that address serious unmet medical needs and could help thousands more patients.